nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
ABCG2 421C>A polymorphism and high exposure of sunitinib in a patient with renal cell carcinoma
|
Mizuno, T. |
|
|
21 |
6 |
p. 1382-1383 |
artikel |
2 |
Activity of fulvestrant in HER2-overexpressing advanced breast cancer
|
Robertson, J.F.R. |
|
|
21 |
6 |
p. 1246-1253 |
artikel |
3 |
A phase II trial of capecitabine and docetaxel followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) as preoperative treatment in women with stage II/III breast cancer
|
Jinno, H. |
|
|
21 |
6 |
p. 1262-1266 |
artikel |
4 |
Aromatase inhibition in male breast cancer patients: biological and clinical implications
|
Doyen, J. |
|
|
21 |
6 |
p. 1243-1245 |
artikel |
5 |
Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review
|
Welch, S. |
|
|
21 |
6 |
p. 1152-1162 |
artikel |
6 |
Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy
|
Kodaira, M. |
|
|
21 |
6 |
p. 1163-1167 |
artikel |
7 |
Cancer mortality in Europe, 2000–2004, and an overview of trends since 1975
|
La Vecchia, C. |
|
|
21 |
6 |
p. 1323-1360 |
artikel |
8 |
Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy
|
Kim, D.H. |
|
|
21 |
6 |
p. 1179-1188 |
artikel |
9 |
D-dimer as a possible prognostic marker of operable hormone receptor-negative breast cancer
|
Batschauer, A.P.B. |
|
|
21 |
6 |
p. 1267-1272 |
artikel |
10 |
Durable responses to Erlotinib despite KRAS mutations in two patients with metastatic lung adenocarcinoma
|
Ferté, C. |
|
|
21 |
6 |
p. 1385-1387 |
artikel |
11 |
Editorial board
|
|
|
|
21 |
6 |
p. ii-iii |
artikel |
12 |
Effects of chronic hepatitis C infection on the treatment of breast cancer patients
|
Morrow, P.K.H. |
|
|
21 |
6 |
p. 1233-1236 |
artikel |
13 |
Factors affecting the outcome of patients with metastatic leiomyosarcoma treated with doxorubicin-containing chemotherapy
|
Penel, N. |
|
|
21 |
6 |
p. 1361-1365 |
artikel |
14 |
Fatal hemobilia in advanced hepatocellular carcinoma invading biliary tract after treatment with sorafenib and biliary stenting
|
Verset, G. |
|
|
21 |
6 |
p. 1381-1382 |
artikel |
15 |
Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study
|
Rauck, R. |
|
|
21 |
6 |
p. 1308-1314 |
artikel |
16 |
Immunologic recovery following autologous stem-cell transplantation with pre- and posttransplantation rituximab for low-grade or mantle cell lymphoma
|
Kasamon, Y.L. |
|
|
21 |
6 |
p. 1203-1210 |
artikel |
17 |
IMPAKT 2010 Breast Cancer Conference, Brussels, Belgium 6–8 May 2010
|
|
|
|
21 |
6 |
p. 1388 |
artikel |
18 |
Infiltrating ductal carcinoma: infiltrates at the exit site of a central venous access port device
|
Moya Horno, I. |
|
|
21 |
6 |
p. 1377-1379 |
artikel |
19 |
in this issue
|
|
|
|
21 |
6 |
p. 1139 |
artikel |
20 |
Large age and hospital-dependent variation in administration of adjuvant chemotherapy for stage III colon cancer in southern Netherlands
|
van Steenbergen, L.N. |
|
|
21 |
6 |
p. 1273-1278 |
artikel |
21 |
MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients
|
Derenzini, E. |
|
|
21 |
6 |
p. 1173-1178 |
artikel |
22 |
Multicentre phase I/II study of PI-88, a heparanase inhibitor in combination with docetaxel in patients with metastatic castrate-resistant prostate cancer
|
Khasraw, M. |
|
|
21 |
6 |
p. 1302-1307 |
artikel |
23 |
Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy
|
Kollmannsberger, C. |
|
|
21 |
6 |
p. 1296-1301 |
artikel |
24 |
Outcomes after repeated resection for recurrent pulmonary metastases from colorectal cancer
|
Park, J.S. |
|
|
21 |
6 |
p. 1285-1289 |
artikel |
25 |
Pathological and molecular characteristics distinguishing contralateral metastatic from new primary breast cancer
|
Banelli, B. |
|
|
21 |
6 |
p. 1237-1242 |
artikel |
26 |
Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel
|
Sessa, C. |
|
|
21 |
6 |
p. 1315-1322 |
artikel |
27 |
Phase II trial of single-agent oral vinorelbine in elderly (≥70 years) patients with advanced non-small-cell lung cancer and poor performance status
|
Camerini, A. |
|
|
21 |
6 |
p. 1290-1295 |
artikel |
28 |
Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study
|
Mocikova, H. |
|
|
21 |
6 |
p. 1222-1227 |
artikel |
29 |
Preferred and actual participation roles during health care decision making in persons with cancer: a systematic review
|
Tariman, J.D. |
|
|
21 |
6 |
p. 1145-1151 |
artikel |
30 |
Preliminary results of phase II study of capecitabine and gemcitabine (CAP-GEM) in patients with metastatic pretreated thymic epithelial tumors (TETs)
|
Palmieri, G. |
|
|
21 |
6 |
p. 1168-1172 |
artikel |
31 |
Probing the unknown in cancer of unknown primary: which way is the right way?
|
Pentheroudakis, G. |
|
|
21 |
6 |
p. 1143-1144 |
artikel |
32 |
Prognostic value of regulatory T cells, lymphoma-associated macrophages, and MUM-1 expression in follicular lymphoma treated before and after the introduction of monoclonal antibody therapy: a Southwest Oncology Group Study
|
Sweetenham, J.W. |
|
|
21 |
6 |
p. 1196-1202 |
artikel |
33 |
Quantitative analysis of changes in ER, PR and HER2 expression in primary breast cancer and paired nodal metastases
|
Aitken, S.J. |
|
|
21 |
6 |
p. 1254-1261 |
artikel |
34 |
Reply to: Discordant expression of molecular markers between primary and nodal metastases: a histopathological manifestation of the ‘self (stem cell)-seeding’ nature of breast cancer disease?
|
Faratian, D. |
|
|
21 |
6 |
p. 1375 |
artikel |
35 |
Results of European pooled analysis of IORT-containing multimodality treatment for locally advanced rectal cancer: adjuvant chemotherapy prevents local recurrence rather than distant metastases
|
Kusters, M. |
|
|
21 |
6 |
p. 1279-1284 |
artikel |
36 |
Rhus verniciflua Stokes extract as a potential option for treatment of metastatic renal cell carcinoma: report of two cases
|
Lee, S.K. |
|
|
21 |
6 |
p. 1383-1385 |
artikel |
37 |
Salvage chemotherapy with alternating MINE–ESHAP regimen in relapsed or refractory Hodgkin’s lymphoma followed by autologous stem-cell transplantation
|
Fernández de Larrea, C. |
|
|
21 |
6 |
p. 1211-1216 |
artikel |
38 |
Sinusal localization of nodal micrometastases is a prognostic factor in breast cancer
|
Masci, G. |
|
|
21 |
6 |
p. 1228-1232 |
artikel |
39 |
Statin-independent prognosis of patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy
|
Ennishi, D. |
|
|
21 |
6 |
p. 1217-1221 |
artikel |
40 |
Subcutaneous ‘lipoma-like’ B-cell lymphoma associated with HCV infection: a new presentation of primary extranodal marginal zone B-cell lymphoma of MALT
|
Paulli, M. |
|
|
21 |
6 |
p. 1189-1195 |
artikel |
41 |
Survival in high-grade osteosarcoma: improvement over 21 years at a single institution
|
Picci, P. |
|
|
21 |
6 |
p. 1366-1373 |
artikel |
42 |
Table of Contents
|
|
|
|
21 |
6 |
p. iv-vi |
artikel |
43 |
The susceptibility CDKN2 locus may have a role on prognosis of melanoma patients
|
Casula, M. |
|
|
21 |
6 |
p. 1379-1380 |
artikel |
44 |
Trastuzumab before breast surgery: is concurrent administration with anthracycline-containing chemotherapy necessary?
|
Del Mastro, L. |
|
|
21 |
6 |
p. 1376-1377 |
artikel |
45 |
Treatment of adult-onset Langerhans cell histiocytosis—is it different from the pediatric approach?
|
Gadner, H. |
|
|
21 |
6 |
p. 1141-1142 |
artikel |